Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

Study limitation reported by the research below: “IcoSema is not yet approved in all markets as of the paper's publication date (August 2026); regulatory status should be verified before clinical application.”